Lufeng Zheng

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Topics

Breast Cancer Cells

Radical Prostatectomy

Epidermal Growth Factor Receptor

Top Venues

Molecules (Basel, Switzerland)

Journal of medicinal chemistry

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Cellular and molecular life sciences : CMLS

This page only lists publications with an associated author ORCID identifier.

Publications

Xinyue Gu, Fang Wei, Jinzhe Tong, Yichen Liu, Simiao Chen, Lufeng Zheng, Yingying Xing
MiR-9 promotes G-MDSC recruitment and tumor proliferation by targeting SOCS3 in breast cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 38 (1) (2024)
Lufeng Zheng, Yuxin Zhang, Shuang Mei, Tianyuan Xie, Yunting Zou, Yuting Wang, Han Jing, Shengtao Xu, Pierre Dramou, Zhen Xu, Jindong Li, Yang Zhou, Miao-Miao Niu
Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer. Journal of medicinal chemistry 67 (9) (2024)
Lufeng Zheng, Yuxin Zhang, Shuang Mei, Tianyuan Xie, Yunting Zou, Yuting Wang, Han Jing, Shengtao Xu, Pierre Dramou, Zhen Xu, Jindong Li, Yang Zhou, Miao-Miao Niu
Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer. Journal of medicinal chemistry (2024)
Xinyue Gu, Fang Wei, Jinzhe Tong, Yichen Liu, Simiao Chen, Lufeng Zheng, Yingying Xing
MiR-9 promotes G-MDSC recruitment and tumor proliferation by targeting SOCS3 in breast cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 38 (1) (2024)
Xinyue Gu, Fang Wei, Jinzhe Tong, Yichen Liu, Simiao Chen, Lufeng Zheng, Yingying Xing
MiR-9 promotes G-MDSC recruitment and tumor proliferation by targeting SOCS3 in breast cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 38 (1) (2024)
Tianyuan Xie, Hai Qin, Zhengdong Yuan, Yiwen Zhang, Xiaoman Li, Lufeng Zheng
Emerging Roles of RNF168 in Tumor Progression. Molecules (Basel, Switzerland) 28 (3) (2023)
Yin Yuan, Hai Qin, Huilong Li, Wanjin Shi, Lichen Bao, Shengtao Xu, Jun Yin, Lufeng Zheng
The Functional Roles of ISG15/ISGylation in Cancer. Molecules (Basel, Switzerland) 28 (3) (2023)
Lufeng Zheng, Yunting Zou, Tianyuan Xie, Xiuyuan Wu, Yuchen Tan, Shuang Mei, Yifei Geng, Shutong Chen, Shengtao Xu, Miao-Miao Niu
Discovery of a Dual Tubulin and Neuropilin-1 (NRP1) Inhibitor with Potent In Vivo Anti-Tumor Activity via Pharmacophore-based Docking Screening, Structure Optimization, and Biological Evaluation. Journal of medicinal chemistry 66 (23) (2023)
Tianyuan Xie, Hai Qin, Zhengdong Yuan, Yiwen Zhang, Xiaoman Li, Lufeng Zheng
Emerging Roles of RNF168 in Tumor Progression. Molecules (Basel, Switzerland) 28 (3) (2023)
Xinyue Gu, Fang Wei, Jinzhe Tong, Yichen Liu, Simiao Chen, Lufeng Zheng, Yingying Xing
MiR-9 promotes G-MDSC recruitment and tumor proliferation by targeting SOCS3 in breast cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 38 (1) (2023)
Yin Yuan, Hai Qin, Huilong Li, Wanjin Shi, Lichen Bao, Shengtao Xu, Jun Yin, Lufeng Zheng
The Functional Roles of ISG15/ISGylation in Cancer. Molecules (Basel, Switzerland) 28 (3) (2023)
Yin Yuan, Hai Qin, Huilong Li, Wanjin Shi, Lichen Bao, Shengtao Xu, Jun Yin, Lufeng Zheng
The Functional Roles of ISG15/ISGylation in Cancer. Molecules (Basel, Switzerland) 28 (3) (2023)
Tianyuan Xie, Hai Qin, Zhengdong Yuan, Yiwen Zhang, Xiaoman Li, Lufeng Zheng
Emerging Roles of RNF168 in Tumor Progression. Molecules (Basel, Switzerland) 28 (3) (2023)
Yichen Liu, Ying Chen, Qiong Zhao, Tianyuan Xie, Chenxi Xiang, Qianqian Guo, Wenzhou Zhang, Yi Zhou, Yin Yuan, Yuxin Zhang, Tao Xi, Xiaoman Li, Lufeng Zheng
A positive TGF-β/miR-9 regulatory loop promotes the expansion and activity of tumour-initiating cells in breast cancer. British journal of pharmacology (2023)
Yin Yuan, Hong Yao, Manzhen Zhou, Xiaoqian Ma, Yi Zhou, Jinyi Xu, Miao-Miao Niu, Jun Yin, Lufeng Zheng, Shengtao Xu
Identification of a Novel Potent CYP4Z1 Inhibitor Attenuating the Stemness of Breast Cancer Cells through Lead Optimization. Journal of medicinal chemistry 65 (23) (2022)
Yue Yang, Yuanyuan Lu, Chunhua Zhang, Qianqian Guo, Wenzhou Zhang, Ting Wang, Zhuolu Xia, Jing Liu, Xiangyu Cheng, Tao Xi, Feng Jiang, Lufeng Zheng
Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis. Cellular and molecular life sciences : CMLS 79 (7) (2022)
Hai Liu, Hai Qin, Yi Zhou, Yin Yuan, Yichen Liu, Ying Chen, Yue Yang, Haiwei Ni, Tao Xi, Lufeng Zheng
HET0016 attenuates the stemness of breast cancer cells through targeting CYP4Z1. Molecular carcinogenesis 60 (6) (2021)
Jinhang Hu, Xiaoman Li, Xinwei Guo, Qianqian Guo, Chenxi Xiang, Zhiting Zhang, Yingying Xing, Tao Xi, Lufeng Zheng
The CCR2 3'UTR functions as a competing endogenous RNA to inhibit breast cancer metastasis. Journal of cell science 130 (19) (2017)